Beijing KEY-BIO Biotech Co.,Ltd.

Development

Development

  • 2007~2009
  • 2010~2019
  • 2020~2021

2007

At the beginning of the company's establishment, it was committed to the development of hepatitis B two half and half test antigen antibody.

2008

The chemiluminescence substrate was developed; A number of monoclonal antibodies against tumor markers were developed.

2009

The monoclonal antibody, polyclonal antibody and marker of HIV-1 p24 were developed, and the joint test of HIV antigen and antibody was established.